CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.
Blast phase
CD19 CAR-T cells
Chronic myeloid leukemia
Refractory leukemia
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
21 Sep 2024
21 Sep 2024
Historique:
received:
30
07
2024
accepted:
12
09
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Chronic myeloid leukemia presenting de novo in the blast phase (CML-BP) is a rare diagnosis among pediatric malignancies. We report on a 16-year-old male who presented with CML-BP lymphoid at diagnosis. He was treated with shortened acute lymphoblastic leukemia induction plus the tyrosine kinase inhibitor (TKI) imatinib followed by dasatinib. After achieving molecular remission (MR), hematopoietic stem cell transplantation (HSCT) was performed early after diagnosis. Despite prophylactic dasatinib, he relapsed 3 months later with the kinase domain mutation T315I. Multiple therapeutic approaches including ponatinib, blinatumomab, a 2nd HSCT from a different donor, donor lymphocyte infusions, and high-dose asciminib all resulted in subsequent relapse. Another molecular response was achieved by combining ponatinib plus asciminib with chemotherapy. In this situation, CD19-directed CAR-T cells (Kymriah
Identifiants
pubmed: 39304585
doi: 10.1007/s00277-024-06011-4
pii: 10.1007/s00277-024-06011-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Hunger SP (2017) CML in blast crisis: more common than we think? Blood 129(20):2713–2714. https://doi.org/10.1182/blood-2017-04-776369
doi: 10.1182/blood-2017-04-776369
pubmed: 28522462
Hijiya N, Suttorp M (2019) How I treat chronic myeloid leukemia in children and adolescents. Blood 133(22):2374–2384. https://doi.org/10.1182/blood.2018882233
doi: 10.1182/blood.2018882233
pubmed: 30917954
Senapati J, Jabbour E, Kantarjian H, Short NJ (2023) Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia 37(1):5–17. https://doi.org/10.1038/s41375-022-01736-5
doi: 10.1038/s41375-022-01736-5
pubmed: 36309558
Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, De Moerloose B, Osborn M, Schultz KR, Sedlacek P, Giona F, Zwaan CM, Shimada H, Versluijs B, Millot F, Hijiya N, Suttorp M, Metzler M (2023) Management of children and adolescents with chronic myeloid leukemia in blast phase: international pediatric CML expert panel recommendations. Leukemia 37(3):505–517. https://doi.org/10.1038/s41375-023-01822-2
doi: 10.1038/s41375-023-01822-2
pubmed: 36707619
pmcid: 9991904
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen J, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D (2024) Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38(7):1522–1533. https://doi.org/10.1038/s41375-024-02278-8
doi: 10.1038/s41375-024-02278-8
pubmed: 38755421
pmcid: 11217003
Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, Ifversen M, Muller I, Stein J, Vettenranta K, Kropshofer G, Kolenova A, Karlhuber S, Glogova E, Poetschger U, Peters C, Suttorp M, Matthes-Leodolter S, Balduzzi A (2024) Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: a prospective multicentre trial of the I-BFM Study Group. Br J Haematol 205(1):268–279. https://doi.org/10.1111/bjh.19535
doi: 10.1111/bjh.19535
pubmed: 38803040
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A (2021) Effect of Blinatumomab vs Chemotherapy on event-free survival among children with high-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: a Randomized Clinical Trial. JAMA 325(9):843–854. https://doi.org/10.1001/jama.2021.0987
doi: 10.1001/jama.2021.0987
pubmed: 33651091
pmcid: 7926287
Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Gungor T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M, Group IS, von Stackelberg A, IntRe ALLSG, Balduzzi A, Group IBSS, Corbacioglu S, Party EPDW, Bader P (2021) Total body irradiation or Chemotherapy Conditioning in Childhood ALL: a multinational, randomized, Noninferiority Phase III Study. J Clin Oncol 39(4):295–307. https://doi.org/10.1200/JCO.20.02529
doi: 10.1200/JCO.20.02529
pubmed: 33332189
Shimada H, Tanizawa A, Kondo T, Nagamura-Inoue T, Yasui M, Tojo A, Muramatsu H, Eto T, Doki N, Tanaka M, Sato M, Noguchi M, Uchida N, Takahashi Y, Sakata N, Ichinohe T, Hashii Y, Kato K, Atsuta Y, Ohashi K, PACMLMPNWGJST, CT (2022) Prognostic factors for outcomes of allogeneic HSCT for children and Adolescents/Young adults with CML in the TKI era. Transpl Cell Ther 28(7):376–389. https://doi.org/10.1016/j.jtct.2022.04.011
doi: 10.1016/j.jtct.2022.04.011
Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Orti G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W (2020) The role of Donor Lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era. Biol Blood Marrow Transpl 26(6):1137–1143. https://doi.org/10.1016/j.bbmt.2020.02.006
doi: 10.1016/j.bbmt.2020.02.006
Sponseiler I, Bandian AM, Pusic P, Lion T (2024) Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias. Am J Hematol 99(1):E9–E11. https://doi.org/10.1002/ajh.27095
doi: 10.1002/ajh.27095
pubmed: 38085116
Zerbit J, Tamburini J, Goldwirt L, Decroocq J, Cayuela JM, Chapuis N, Contejean A, Batista R, Bouscary D, Willems L (2021) Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma 62(14):3558–3560. https://doi.org/10.1080/10428194.2021.1966787
doi: 10.1080/10428194.2021.1966787
pubmed: 34405773
Zhang H, Hu Y, Chang AH, Huang H (2020) Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib. Regen Ther 14:40–42. https://doi.org/10.1016/j.reth.2019.11.003
doi: 10.1016/j.reth.2019.11.003
pubmed: 31988993
pmcid: 6965727
Liu Y, Tu Y, Xiao J, Shen Y, Zhou B, Yang Q, Yu L, Qi L, Chen J, Liu T, Wu D, Xu Y (2024) Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy. Blood Cancer J 14(1):39. https://doi.org/10.1038/s41408-024-01020-y
doi: 10.1038/s41408-024-01020-y
pubmed: 38448401
pmcid: 10917735